There has been substantial activity surrounding
Amgen Inc. as evident in the recent market transactions. A number of investment firms and asset management companies like Triumph Capital Management, the Czech National Bank, and StrongBox Wealth LLC have purchased new stakes or increased their shareholding in Amgen. Meanwhile, Dynamic Advisor Solutions LLC, Leibman Financial Services, and others have sold significant portions of their Amgen stock. As far as analysts' opinions go, the consensus seems to lean towards a
'Hold' rating. Despite this, Amgen's stock has shown optimal performance in the trading market. Guggenheim has maintained a
'Hold' on Amgen Inc. The biotech giant's SWOT analysis also outlines the challenges it faces in the competitive market. On a promising note,
Amgen has gained FDA approval for broadening Repatha's use in cardiovascular risk management and revealed the release of top-line results from their
ASCEND study of Rocatinlimab. The company continues its innovation drive with an
investment of over half a billion dollars towards a new state-of-the-art Center for Science and Innovation at its global headquarters in the U.S.
Amgen AMGN News Analytics from Thu, 03 Jul 2025 07:00:00 GMT to Sun, 21 Sep 2025 00:10:09 GMT -
Rating 5
- Innovation 7
- Information 9
- Rumor 2
